Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
SALT LAKE CITY, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the closing of a registered direct offering of common stock to existing shareholders, including insiders, with total gross proceeds of $4 million.